Alps Advisors Inc. bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,193 shares of the company’s stock, valued at approximately $459,000.
Several other institutional investors also recently modified their holdings of ZTS. Candriam Luxembourg S.C.A. grew its stake in Zoetis by 8.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 51,163 shares of the company’s stock valued at $3,262,000 after acquiring an additional 3,943 shares during the last quarter. Swiss National Bank boosted its position in shares of Zoetis by 0.7% in the third quarter. Swiss National Bank now owns 1,809,280 shares of the company’s stock worth $115,360,000 after acquiring an additional 12,900 shares during the last quarter. Fiduciary Trust Co. boosted its position in shares of Zoetis by 7.1% in the third quarter. Fiduciary Trust Co. now owns 14,078 shares of the company’s stock worth $898,000 after acquiring an additional 930 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Zoetis by 8.6% in the third quarter. Daiwa Securities Group Inc. now owns 16,131 shares of the company’s stock worth $1,029,000 after acquiring an additional 1,281 shares during the last quarter. Finally, Rockland Trust Co. raised its holdings in Zoetis by 2.8% in the third quarter. Rockland Trust Co. now owns 127,971 shares of the company’s stock valued at $8,159,000 after buying an additional 3,532 shares during the period. Institutional investors and hedge funds own 93.33% of the company’s stock.
Shares of Zoetis Inc. (NYSE ZTS) traded up $0.12 during mid-day trading on Wednesday, hitting $70.97. The stock had a trading volume of 1,507,421 shares, compared to its average volume of 2,772,501. The company has a market capitalization of $34,607.21, a PE ratio of 32.58, a PEG ratio of 2.13 and a beta of 1.06. Zoetis Inc. has a 12 month low of $49.79 and a 12 month high of $72.79. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
The business also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Thursday, November 9th were paid a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.59%. The ex-dividend date was Wednesday, November 8th. Zoetis’s payout ratio is 22.11%.
Several research firms recently commented on ZTS. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a report on Thursday, October 12th. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Wednesday, September 6th. BidaskClub downgraded shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley boosted their price target on shares of Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $68.24.
TRADEMARK VIOLATION WARNING: This report was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/12/06/7193-shares-in-zoetis-inc-zts-acquired-by-alps-advisors-inc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.